Your browser doesn't support javascript.
loading
Bumetanide Oral Liquid Formulation for the Treatment of Children and Adolescents with Autism Spectrum Disorder: Design of Two Phase III Studies (SIGN Trials).
Crutel, Véronique; Lambert, Estelle; Penelaud, Pierre-François; Albarrán Severo, Cristina; Fuentes, Joaquin; Rosier, Antoine; Hervás, Amaia; Marret, Stéphane; Oliveira, Guiomar; Parellada, Mara; Kyaga, Simon; Gouttefangeas, Sylvie; Bertrand, Marianne; Ravel, Denis; Falissard, Bruno.
Afiliação
  • Crutel V; Neuro Immuno-Inflammation Therapeutic Area, Institut de Recherches Internationales Servier, Suresnes, France.
  • Lambert E; Neuro Immuno-Inflammation Therapeutic Area, Institut de Recherches Internationales Servier, Suresnes, France.
  • Penelaud PF; Neuro Immuno-Inflammation Therapeutic Area, Institut de Recherches Internationales Servier, Suresnes, France.
  • Albarrán Severo C; Neuro Immuno-Inflammation Therapeutic Area, Institut de Recherches Internationales Servier, Suresnes, France.
  • Fuentes J; Child & Adolescent Psychiatry Service, Policlínica Gipuzkoa & GAUTENA Autism Society, San Sebastián, Spain.
  • Rosier A; Department of Neonatal Pediatrics, CHU de Rouen and CHU Le Rouvray, Sotteville les Rouen, France.
  • Hervás A; Child and Adolescent Mental Health Service, Hospital Universitari Mútua de Terrassa, and Global Institute of Neurodevelopment Integrated Care (IGAIN), Barcelona, Spain.
  • Marret S; Department of Neonatal Pediatrics, Intensive Care, and Neuropediatrics, Rouen University Hospital, Rouen, France.
  • Oliveira G; INSERM U 1245 team 4 Neovasc, School of Medicine, Normandy University, Rouen, France.
  • Parellada M; Neurodevelopmental and Autism Unit from Child Developmental Center and Centro de Investigação e Formação Clínica, Hospital Pediátrico, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal.
  • Kyaga S; Faculty of Medicine, University Clinic of Pediatrics, University of Coimbra, Coimbra, Portugal.
  • Gouttefangeas S; Servicio de Psiquiatría del Niño y del Adolescente Hospital General Universitario Gregorio Marañón, CIBERSAM, IiSGM, Ibiza 43, Madrid, Spain.
  • Bertrand M; Global Medical and Patient Affairs, Servier, 35 rue de Verdun, 92284, Suresnes cedex, Suresnes, France. simon.kyaga@servier.com.
  • Ravel D; Neuro Immuno-Inflammation Therapeutic Area, Institut de Recherches Internationales Servier, Suresnes, France.
  • Falissard B; Neuro Immuno-Inflammation Therapeutic Area, Institut de Recherches Internationales Servier, Suresnes, France.
J Autism Dev Disord ; 51(8): 2959-2972, 2021 Aug.
Article em En | MEDLINE | ID: mdl-33151500
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Projetos de Pesquisa / Comportamento Social / Bumetanida / Transtorno do Espectro Autista Tipo de estudo: Clinical_trials Limite: Adolescent / Child / Child, preschool / Humans / Male Idioma: En Revista: J Autism Dev Disord Ano de publicação: 2021 Tipo de documento: Article País de afiliação: França
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Projetos de Pesquisa / Comportamento Social / Bumetanida / Transtorno do Espectro Autista Tipo de estudo: Clinical_trials Limite: Adolescent / Child / Child, preschool / Humans / Male Idioma: En Revista: J Autism Dev Disord Ano de publicação: 2021 Tipo de documento: Article País de afiliação: França